Literature DB >> 19215002

KIR-HLA receptor-ligand mismatch associated with a graft-versus-tumor effect in haploidentical stem cell transplantation for pediatric metastatic solid tumors.

Antonio Pérez-Martínez1, Wing Leung, Evangelina Muñoz, Rekha Iyengar, Manuel Ramírez, José Luis Vicario, Alvaro Lassaletta, Julián Sevilla, Marta González-Vicent, Luis Madero, Miguel Angel Díaz-Pérez.   

Abstract

Killer immunoglobulin-like receptors (KIRs) on natural killer cells (NKs) recognize groups of human leukocyte antigen (HLA) class I alleles. Cells without an inhibitory HLA ligand may trigger NK activation. Reduced risk of relapse has been reported in malignant hematologic diseases after haploidentical transplantation when HLA ligands against the inhibitory KIRs present in the donor were absent in the recipient. We performed haploidentical transplant in three children with refractory solid tumors. Our results showed that beneficial antitumor effects could be observed in the presence of inhibitory KIR-HLA mismatch. These preliminary results suggest a possible association between disease control and NK cell alloreactivity. Copyright 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19215002     DOI: 10.1002/pbc.21955

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  32 in total

1.  Association of the genetic diversity of killer cell immunoglobulin-like receptor genes and HLA-C ligand in Saudi women with breast cancer.

Authors:  Suliman Y Alomar; Afrah Alkhuriji; Paul Trayhyrn; Abdulkarim Alhetheel; Abdullah Al-Jurayyan; Lamjed Mansour
Journal:  Immunogenetics       Date:  2016-09-15       Impact factor: 2.846

2.  Reduced-Intensity Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Solid Tumors in Pediatric and Young Adult Patients.

Authors:  Nicolas J Llosa; Kenneth R Cooke; Allen R Chen; Christopher J Gamper; Orly R Klein; Elias T Zambidis; Brandon Luber; Gary Rosner; Nicholas Siegel; Mary Jo Holuba; Nancy Robey; Masanori Hayashi; Richard J Jones; Ephraim Fuchs; Matthias Holdhoff; David M Loeb; Heather J Symons
Journal:  Biol Blood Marrow Transplant       Date:  2017-08-12       Impact factor: 5.742

3.  Favorable NK cell activity after haploidentical hematopoietic stem cell transplantation in stage IV relapsed Ewing's sarcoma patients.

Authors:  P Schlegel; T Feuchtinger; C Nitschke-Gérard; U J Eva Seidel; A-M Lang; C Kyzirakos; H-M Teltschik; M Ebinger; M Schumm; E Koscielniak; R Handgretinger; P Lang
Journal:  Bone Marrow Transplant       Date:  2015-06       Impact factor: 5.483

4.  Allogeneic stem cell transplantation for neuroblastoma.

Authors:  Ki Woong Sung
Journal:  Korean J Hematol       Date:  2012-03-28

Review 5.  Immunotherapy in pediatric malignancies: current status and future perspectives.

Authors:  Christian M Capitini; Mario Otto; Kenneth B DeSantes; Paul M Sondel
Journal:  Future Oncol       Date:  2014       Impact factor: 3.404

Review 6.  Advances in chimeric antigen receptor immunotherapy for neuroblastoma.

Authors:  Andras Heczey; Chrystal U Louis
Journal:  Discov Med       Date:  2013-12       Impact factor: 2.970

7.  Killer immunoglobulin-like receptor (KIR) and KIR-ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2.

Authors:  Wei Wang; Amy K Erbe; Mikayla Gallenberger; KyungMann Kim; Lakeesha Carmichael; Dustin Hess; Eneida A Mendonca; Yiqiang Song; Jacquelyn A Hank; Su-Chun Cheng; Sabina Signoretti; Michael Atkins; Alexander Carlson; Jonathan M Weiss; James Mier; David Panka; David F McDermott; Paul M Sondel
Journal:  Cancer Immunol Immunother       Date:  2016-09-30       Impact factor: 6.968

8.  Successful allogeneic hematopoietic cell engraftment after a minimal conditioning regimen in children with relapsed or refractory solid tumors.

Authors:  David R Shook; Brandon M Triplett; Ashok Srinivasan; Christine Hartford; Mari H Dallas; Asha Pillai; Joseph Laver; Wing Leung
Journal:  Biol Blood Marrow Transplant       Date:  2012-10-09       Impact factor: 5.742

9.  Current therapeutic approaches in metastatic and recurrent ewing sarcoma.

Authors:  Michael Huang; Kenneth Lucas
Journal:  Sarcoma       Date:  2010-12-01

Review 10.  Cellular immunotherapy for pediatric solid tumors.

Authors:  Meenakshi Hegde; Alexander J Moll; Tiara T Byrd; Chrystal U Louis; Nabil Ahmed
Journal:  Cytotherapy       Date:  2014-07-28       Impact factor: 5.414

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.